Real-World study tests migraine prevention pill in UK clinics

NCT ID NCT07690215

Not yet recruiting Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study looks at how well atogepant, a daily pill, works to prevent migraines in adults treated in UK primary care. About 200 people with migraine will take atogepant as prescribed by their doctor and report their symptoms and healthcare use for up to 48 weeks. The goal is to see if atogepant improves their condition in real-world settings, outside of strict clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atogepant
What this could lead to: If successful, this study could confirm that atogepant works well in everyday primary care settings, helping more people prevent migraines effectively.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. Atogepant may not work for everyone and can cause side effects like nausea or constipation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.